Supplementary Material for: <b><i>JAK1</i></b> rs310241 and <b><i>JAK3</i></b> rs3008 Genotypes May Increase Susceptibility to Psoriasis: A Case Control Study

<b><i>Background:</i></b> Janus kinases (JAKs) are a family of non-receptor protein tyrosine kinases that are expressed in a variety of tissues. Several JAK-controlled cytokine receptor pathways are incriminated in the initiation and progression of psoriasis. Genetic polymorphisms influencing JAK expression would be anticipated to have a great impact on disease activity. <b><i>Objective:</i></b> The aim of the study was to evaluate the association between <i>JAK1</i> rs310241 and <i>JAK3</i> rs3008 polymorphisms and the risk of developing psoriasis. <b><i>Methods:</i></b> Blood samples of 150 patients and 120 controls were screened for nucleotide polymorphisms in <i>JAK1</i> rs310241 and <i>JAK3</i> rs3008 genes by using polymerase chain reaction<b> (</b>PCR)-restriction fragment length polymorphism technique. <b><i>Results:</i></b> The GG genotype of the <i>JAK1</i> rs310241 and <i>JAK3 rs3008</i> genes was significantly associated with an increase in psoriasis risk (<i>p</i> = 0.000, OR = 7.7, 95% CI = 2.8–21.5; <i>p</i> = 0.003, OR = 3.3, 95% CI = 1.5–6.9, respectively). The G allele of both genes was also associated with psoriasis susceptibility (<i>p</i> = 0.000, OR = 2.0, 95% CI = 1.4–2.8; <i>p</i> = 0.002, OR = 1.7, 95% CI = 1.2–2.4, respectively). <b><i>Conclusion:</i></b> The results indicate a possible association between <i>JAK1</i> rs310241 and <i>JAK3</i> rs3008 gene polymorphisms and susceptibility to psoriasis. These findings validate the importance of these molecules in psoriasis and may enable the identification of the individuals most susceptible to the disease.